Skip To Main Content
Burson Buchanan on Muck Rack

Burson Buchanan

As seen in: This is Money, ADVFN-UK, PR Week, Sharecastcom, FE Investegate, Ariva.de AG, rank.com, Vox Markets
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Burson

Contact Burson, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Block Listing Six Monthly Return

|
By Burson Buchanan
| FE Investegate Verified
I am a Private Investor *A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: Obtains access to the information in a personal capacity; Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority,...
Open in Who Shared View Duplicates (13) Issue with article?

Sale of shares from Treasury

|
By Burson Buchanan
| FE Investegate Verified
Bellevue Healthcare Trust plc announced that Threadneedle Asset Management Holdings Limited (TAMHL) will invest approximately £18.68 million by purchasing 13,107,524 ordinary redeemable shares from treasury at 142.57 pence per share, which equals the prevailing Net Asset Value per Share. This transaction is expected to occur on March 10, 2026. Following this, the Company will hold 258,768,113 shares in treasury, with 56,384,196 shares in issue, representing the total voting rights.
Open in Who Shared View Duplicates (283) Issue with article?

CRISM Therapeutics Corporation Japanese Patent Grant

|
By Burson Buchanan, Andrew Webb, Chris McConville
| ADVFN-UK
RNS Number : 5029P CRISM Therapeutics Corporation 20 January 2026 20 January 2026 CRISM Therapeutics Corporation ("CRISM", "CRISM Therapeutics" or the "Company") Japanese Patent Grant for ChemoSeed CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announces that it has been granted a patent (7800909) by the Japanese Patent Office.
Open in Who Shared View Duplicates (3) Issue with article?
See all 20 licensed articles (29 Total)